Current management of the menopause vs Selective estrogen receptor modulators

Current management of the menopause

Christian Lauritzen, John Studd

2005

In the next few decades, an estimated one billion women will reach menopause. They will depend on the preventative measures, management, and advice provided to them by their gynecologist or general practitioner. At a time when doubts and criticisms have been raised concerning the real benefit and the justification of peri- to postmenopausal estroge

Selective estrogen receptor modulators

Andrea Manni

2001

Experimental and clinical researchers from a wide range of disciplines present a wealth of fresh scientific information on the biochemistry, molecular biology, pharmacology, and clinical activity of SERMs. The basic science chapters of the book focus-with an eye to the development of the ideal SERM-on the complex mechanisms of estrogen action, including ligand-dependent conformational changes in alpha and beta, and the recruitment of co-activators and co-repressors which modulate the estrogen receptor transcriptional activity and contribute to its crosstalk with growth factor signaling. The clinical presentation reviews the data accumulated on currently available SERMs, primarily tamoxifen and raloxifene, in cancer treatment and prevention, as well as their effects on the reproductive, vascular, skeletal, and central nervous systems. A tentative approach to menopause-related health issues is also provided for women with and without a previous diagnosis of localized breast cancer.